Kaplan-Meier metastasis-free survival curves for ER+/HER2− breast cancers. (A) Curves representing EndoPredict (EP) test results indicating estimated high and low risk of metastasis-free survival (MFS). The cutoff point was prespecified at 5. (B) Curves representing EPclin results indicating estimated high and low risk of MFS. The cutoff point was prespecified at 3.3. Numbers in parentheses indicate the 95% confidence intervals of the hazard ratios. ARR: Absolute risk reduction estimated at 10 years; ER+/HER2−: Estrogen receptor–positive/human epidermal growth factor receptor 2–negative. The MFS in the EP score–based low-risk category was 93% vs 70% in the EP score–based high-risk group. The MFS in the EPclin-based low-risk category was 100% vs 72% in the EPclin score–based high-risk group.